AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34065698 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 17
Study 32745938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence spectroscopy at 450 nm excitation wavelength
Number of subjects: 0
Study 32745938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence spectroscopy at 385 nm and 405 nm excitation wavelengths
Number of subjects: 0
Study 32745938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse reflectance spectroscopy (DRS) measurements
Number of subjects: 0
Study 35654307 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire Supraclavicular Nodal Irradiation (E-SCLI)
Number of subjects: 544
Study 35654307 — intervention group
Group type: COMPARATOR
Intervention: Medial Supraclavicular Nodal Irradiation (M-SCLI)
Number of subjects: 544
Study 33787615 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group (P-G)
Number of subjects: 41
Study 33787615 — intervention group
Group type: COMPARATOR
Intervention: General physical activity program group (Pa-G)
Number of subjects: 41
Study 35623841 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.3 g (Low) essential amino acid enriched whey protein supplement
Number of subjects: 8
Study 35623841 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.6 g (High) essential amino acid enriched whey protein supplement
Number of subjects: 8
Study 34240694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 10
Study 35685534 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (1.8 × 10^9 CFU/day)
Number of subjects: 70
Study 32507383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1
Study 32507383 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1
Study 32507383 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1
Study 35773956 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Parenting App (SPA)
Number of subjects: 33
Study 35773956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 33
Study 33757875 — intervention group
Group type: EXPERIMENTAL
Intervention: TBscore intervention
Number of subjects: 3571
Study 34586711 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation
Number of subjects: 9
Study 34586711 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (dose ≤1,000 mg/day)
Number of subjects: 9
Study 34586711 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (>10-week intervention)
Number of subjects: 9
Study 34586711 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin consumption (less than 2000 mg/day)
Number of subjects: 9
Study 34953926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 34953926 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study 34953926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study 33434288 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating selected metabolites (27 identified metabolites) into fracture risk prediction models.
Number of subjects: 1552
Study 33434288 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected metabolites from the glycine, serine, and threonine metabolism pathway (creatine, dimethylglycine, glycine, and serine).
Number of subjects: 1552
Study 33434288 — intervention group
Group type: EXPERIMENTAL
Intervention: Causally related metabolites (glycine, phosphatidylcholine [PC], and triacylglycerol [TAG]).
Number of subjects: 1552
Study 34402121 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant message-based lifestyle and stress management intervention for 5 months
Number of subjects: 164
Study 34402121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instant message intervention)
Number of subjects: 164
Study 33285707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-propofol combination (Group D)
Number of subjects: 60
Study 33285707 — intervention group
Group type: COMPARATOR
Intervention: Ketamine-propofol combination (Group K)
Number of subjects: 60
Study 33285707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 33743777 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote knowledge broker offering tailored support via phone and email (group A)
Number of subjects: 2765
Study 33743777 — intervention group
Group type: COMPARATOR
Intervention: Generalised monthly email focused on tobacco and depression treatment (group B)
Number of subjects: 2765
Study 33743777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost minimisation analysis
Number of subjects: 2765
Study 34131942 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Omecamtiv mecarbil (OM)
Number of subjects: 60
Study 34131942 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin
Number of subjects: 60
Study 34131942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34560383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2 with nimotuzumab once a week with curative radiotherapy
Number of subjects: 536
Study 34560383 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 30 mg/m2 alone
Number of subjects: 536
Study 33591290 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth behavior change intervention (educational sessions and 8-week physical activity goal setting using Fitbit and SMS)
Number of subjects: 49
Study 33591290 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth behavior change intervention
Number of subjects: 49
Study 32868698 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized heating on postoperative days 3 and 4
Number of subjects: 58
Study 32868698 — intervention group
Group type: COMPARATOR
Intervention: Normothermia without localized heating
Number of subjects: 58
Study 35157136 — intervention group
Group type: EXPERIMENTAL
Intervention: iPACK + ACB
Number of subjects: 105
Study 35157136 — intervention group
Group type: COMPARATOR
Intervention: PAI + ACB
Number of subjects: 105
Study 35157136 — intervention group
Group type: COMPARATOR
Intervention: ACB
Number of subjects: 105
Study 34243388 — intervention group
Group type: EXPERIMENTAL
Intervention: New, improved CECE coherency‐based analysis for calculating temperature fluctuation frequency spectrum and level
Number of subjects: 0
Study 34243388 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for calculating noise levels
Number of subjects: 0
Study 34243388 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct calculation of system noise level using correlation between randomized intermediate frequency signals
Number of subjects: 0
Study 33599340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberry supplementation (1.4 g/day of extract) for 4 weeks
Number of subjects: 20
Study 33599340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32107374 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adjusted therapy for standard risk patients
Number of subjects: 1138
Study 32107374 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adjusted therapy for high risk patients
Number of subjects: 1138
Study 32107374 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adjusted therapy for extremely high risk patients
Number of subjects: 1138
Study 32107374 — intervention group
Group type: EXPERIMENTAL
Intervention: NCI risk classification for standard risk patients
Number of subjects: 1138
Study 32107374 — intervention group
Group type: EXPERIMENTAL
Intervention: NCI risk classification for high risk patients
Number of subjects: 1138
Study 32107374 — intervention group
Group type: COMPARATOR
Intervention: Comparison to previous trial ALL-97 for NCI-SR patients
Number of subjects: 1138
Study 32107374 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS relapse rates
Number of subjects: 1138
Study 36282170 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous tranexamic acid (TXA) administered 15 min before incision in 100 cc of saline
Number of subjects: 102
Study 36282170 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 102
Study 36282170 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous tranexamic acid (TXA)
Number of subjects: 102
Study 32915346 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-port endodontic needles (NI) without agitation
Number of subjects: 160
Study 32915346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic activation using EDDY
Number of subjects: 160
Study 32915346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic activation using EndoActivator (EA)
Number of subjects: 160
Study 32915346 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI)
Number of subjects: 160
Study 32915346 — intervention group
Group type: COMPARATOR
Intervention: Control group (NI)
Number of subjects: 160
Study 33109037 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine tablet (5mg)
Number of subjects: 56
Study 33109037 — intervention group
Group type: COMPARATOR
Intervention: AERIUS (5mg)
Number of subjects: 56
Study 33109037 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8 and UGT2B10 genotypes
Number of subjects: 56
Study 36181017 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic cartilage regeneration facilitating procedure (ACRFP)
Number of subjects: 411
Study 33620662 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Mindfully (PM) intervention
Number of subjects: 96
Study 33620662 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Mindfully (PM) intervention (secondary analysis)
Number of subjects: 96
Study 33620662 — intervention group
Group type: COMPARATOR
Intervention: Brief parent education (PE) control group
Number of subjects: 96
Study 35365713 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic pretreatment
Number of subjects: 22
Study 35365713 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic pretreatment (Control)
Number of subjects: 22
Study 35365713 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsules (maintenance dose delivery)
Number of subjects: 22
Study 35365713 — intervention group
Group type: EXPERIMENTAL
Intervention: Enema (maintenance dose delivery)
Number of subjects: 22
Study 32249726 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood ADHD
Number of subjects: 8310
Study 32249726 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD genetic liability
Number of subjects: 8310
Study 32316561 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding (TRF)
Number of subjects: 26
Study 32316561 — intervention group
Group type: COMPARATOR
Intervention: Normal Diet (ND)
Number of subjects: 26
Study 35370419 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrolaminar block (RLB)
Number of subjects: 0
Study 35370419 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 0
Study 33025323 — intervention group
Group type: EXPERIMENTAL
Intervention: CARDEAN
Number of subjects: 76
Study 33739473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Care Bridge (CCB) program
Number of subjects: 18
Study 33739473 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of (in)formal caregivers
Number of subjects: 18
Study 33739473 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB caregivers
Number of subjects: 18
Study 33739473 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment of patients and informal caregivers
Number of subjects: 18
Study 33739473 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of early signs of deterioration
Number of subjects: 18
Study 33739473 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of patients' care needs and expectations
Number of subjects: 18
Study 33650840 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 200
Study 33650840 — intervention group
Group type: COMPARATOR
Intervention: Traditional kinesiotherapy
Number of subjects: 200
Study 33650840 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including manual therapy, PNF, combined therapy, and traditional kinesiotherapy)
Number of subjects: 200
Study 33650840 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and PNF
Number of subjects: 200
Study 33270062 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK abutment with LD crown
Number of subjects: 40
Study 33270062 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK abutment with TZ crown
Number of subjects: 40
Study 33270062 — intervention group
Group type: EXPERIMENTAL
Intervention: YZ abutment with TZ crown
Number of subjects: 40
Study 33270062 — intervention group
Group type: EXPERIMENTAL
Intervention: YZ abutment with LD crown
Number of subjects: 40
Study 36450787 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum oxide flexible disks (Al2O3‐Disks)
Number of subjects: 75
Study 36450787 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon carbide polyester strips (SIC‐Strips)
Number of subjects: 75
Study 36450787 — intervention group
Group type: COMPARATOR
Intervention: Negative control (NC)
Number of subjects: 75
Study 36450787 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including NC)
Number of subjects: 75
Study 33435909 — intervention group
Group type: EXPERIMENTAL
Intervention: nab‐paclitaxel combined with S‐1 (AS)
Number of subjects: 616
Study 33435909 — intervention group
Group type: COMPARATOR
Intervention: oxaliplatin combined with capecitabine (XELOX)
Number of subjects: 616
Study 35772462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus cabozantinib
Number of subjects: 0
Study 35772462 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study 33866489 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-consistent language
Number of subjects: 87
Study 33866489 — intervention group
Group type: COMPARATOR
Intervention: MI-inconsistent language
Number of subjects: 87
Study 33866489 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher factors (age, efficacy, burnout, classroom organization)
Number of subjects: 87
Study 33681652 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (2–12 mg/day)
Number of subjects: 128
Study 33681652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 33130482 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab SC 300 mg single dose
Number of subjects: 96
Study 33130482 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab SC 300 mg once weekly for eight doses
Number of subjects: 96
Study 33130482 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab IV 5 mg/kg once every 4 weeks for two doses
Number of subjects: 96
Study 33130482 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab IV 15 mg/kg once every 4 weeks for two doses
Number of subjects: 96
Study 33130482 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab (IV and SC)
Number of subjects: 96
Study 33130482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 36353577 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood infusion
Number of subjects: 0
Study 36353577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36840609 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE Steps to Success program
Number of subjects: 4
Study 33410493 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led exercise intervention
Number of subjects: 256
Study 33410493 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided subacromial corticosteroid injection
Number of subjects: 256
Study 33410493 — intervention group
Group type: COMPARATOR
Intervention: Standard advice and exercise leaflet
Number of subjects: 256
Study 33410493 — intervention group
Group type: COMPARATOR
Intervention: Unguided injection
Number of subjects: 256
Study 616787743 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer classes and games in virtual reality environment
Number of subjects: 0
Study 34791941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg daily
Number of subjects: 718
Study 34791941 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg daily
Number of subjects: 718
Study 34628736 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery acupuncture
Number of subjects: 64
Study 34628736 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture plus motor imagery therapy at affected lower limb
Number of subjects: 64
Study 32785872 — intervention group
Group type: EXPERIMENTAL
Intervention: TINAD program
Number of subjects: 576
Study 33556601 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping for unruptured MCA aneurysms
Number of subjects: 171
Study 33556601 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling for unruptured MCA aneurysms
Number of subjects: 171
Study 33556601 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management for ruptured MCA aneurysms
Number of subjects: 171
Study 33556601 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular management for ruptured MCA aneurysms
Number of subjects: 171
Study 33556601 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping for unruptured MCA aneurysms (1-year imaging results)
Number of subjects: 171
Study 33556601 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling for unruptured MCA aneurysms (1-year imaging results)
Number of subjects: 171
Study 33556601 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping for ruptured MCA aneurysms (1-year imaging results)
Number of subjects: 171
Study 33556601 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling for ruptured MCA aneurysms (1-year imaging results)
Number of subjects: 171
Study 36074617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 219
Study 36074617 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 219
Study 36074617 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 219
Study 34271135 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional program including home-based standing exercises, health education, and telephone support for 16 weeks
Number of subjects: 43
Study 34271135 — intervention group
Group type: COMPARATOR
Intervention: Control group received orientation regarding the harmful effects of a sedentary lifestyle
Number of subjects: 43
Study 36103390 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg vaccine SCoK
Number of subjects: 0
Study 36103390 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg vaccine SCoK
Number of subjects: 0
Study 36103390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33960007 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week vegan diet
Number of subjects: 0
Study 33960007 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33256795 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin and zinc co-supplementation
Number of subjects: 84
Study 33256795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 35271466 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic methods (TAPP)
Number of subjects: 82
Study 35271466 — intervention group
Group type: COMPARATOR
Intervention: Modified Lichtenstein technique
Number of subjects: 82
Study 34132694 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 104
Study 34132694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 104
Study 34132694 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT)
Number of subjects: 104
Study 34132694 — intervention group
Group type: COMPARATOR
Intervention: RYGB vs IMT
Number of subjects: 104
Study 34132694 — intervention group
Group type: COMPARATOR
Intervention: SG vs IMT
Number of subjects: 104
Study 32682995 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative + AVG
Number of subjects: 210
Study 32682995 — intervention group
Group type: EXPERIMENTAL
Intervention: AVG Only
Number of subjects: 210
Study 32682995 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 210
Study 36394217 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy (CDT)
Number of subjects: 0
Study 36394217 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals without lymphedema)
Number of subjects: 0
Study 32471645 — intervention group
Group type: EXPERIMENTAL
Intervention: Zymomonas mobilis fermented broth once a day
Number of subjects: 13
Study 32471645 — intervention group
Group type: EXPERIMENTAL
Intervention: Zymomonas mobilis fermented broth twice a day
Number of subjects: 13
Study 32471645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free fermented broth once daily
Number of subjects: 13
Study 32471645 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline once daily)
Number of subjects: 13
Study 35339765 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Schools Healthy Students intervention
Number of subjects: 20
Study 33958424 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW + PL intervention
Number of subjects: 222
Study 33958424 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-only intervention
Number of subjects: 222
Study 33958424 — intervention group
Group type: COMPARATOR
Intervention: EUC intervention
Number of subjects: 222
Study 34057705 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day green cardamom
Number of subjects: 194
Study 34057705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 194
Study 34525492 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid after microneedling (TA + microneedling), every other week
Number of subjects: 50
Study 34525492 — intervention group
Group type: COMPARATOR
Intervention: Topical 4% hydroquinone (HQ), nightly application
Number of subjects: 50
Study 34612601 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day initiation (SDI) of antiretroviral therapy (ART)
Number of subjects: 1193
Study 34612601 — intervention group
Group type: COMPARATOR
Intervention: Standard of care initiation procedures
Number of subjects: 1193
Study 34237025 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (QG) group (n = 34) performing Qigong exercises
Number of subjects: 104